Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Connect ® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study

Christopher R. Flowers, David Andorsky, John M. Burke, James R. Cerhan, David L. Grinblatt, Chris L. Pashos, Kathleen Toomey, Andrew D. Zelenetz, Kristen Sullivan, E. Dawn Flick, Pavel Kiselev, Mark Kaplan, Jung Ryun Ahn

Blood (2021) 138 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2021-145135

Published: 2021

Journal Articles

Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Disease Registry

Gail J. Roboz, MD, Christopher R. Cogle, Daniel A. Pollyea, Mehrdad Abedi, MD, Michael A. Thompson, MD PhD, Melissa Nifenecker, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Michelle Little, Harry P. Erba

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-135877

Published: 2020

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami S. Komrokji, MD, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, David P. Steensma

Blood (2018) 132 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2018-99-111145

Published: 2018

Journal Articles

Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect ® MDS/AML Disease Registry

Sudipto Mukherjee, MD PhD MPH, Mehrdad Abedi, MD, Harry P. Erba, MD PhD, Daniel A Pollyea, MD, Gail J. Roboz, MD, Michael A. Thompson, MD PhD FASCO, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 4736.

https://doi.org/10.1182/blood-2018-99-112935

Published: 2018

Journal Articles

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Mohit Narang, MD, Rafat Abonour, MD, Brian G. M. Durie, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Shankar Srinivasan, PhD, E. Dawn Flick, MPH. ScD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3156.

https://doi.org/10.1182/blood.V130.Suppl_1.3156.3156

Published: 2017

Journal Articles

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Cristina J. Gasparetto, MD, Rafat Abonour, MD, Sundar Jagannath, MD, Brian G. M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne Wagner, PhD, Shankar Srinivasan, PhD, Amani Kitali, MBA, MPH, E. Dawn Flick, MPH, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3101.

https://doi.org/10.1182/blood.V130.Suppl_1.3101.3101

Published: 2017

Journal Articles

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Inhye E Ahn, MD, Charles Michael Farber, MD PhD, Matthew Davids, MD, David L. Grinblatt, MD, Nicole Lamanna, MD, Anthony R. Mato, MDMSCE, Chadi Nabhan, MD MBA, FACP, Pavel Kiselev, PhD, Arlene S. Swern, PhD, E. Dawn Flick, RPh, MPH, ScD, Shriya Bhushan, PharmD, Kristen Sullivan, MBA, CCRA, Jeff Sharman, MD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 3581.

https://doi.org/10.1182/blood.V128.22.3581.3581

Published: 2016

Journal Articles

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Jeff Sharman, MD, Matthew Davids, MD, Charles Michael Farber, MD PhD, David L. Grinblatt, MD, Neil E. Kay, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Chadi Nabhan, MD MBA, FACP, Kristen Sullivan, MBA, CCRA, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 5941.

https://doi.org/10.1182/blood.V128.22.5941.5941

Published: 2016

Journal Articles

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Charles M. Farber, MD, Anthony Mato, MD, Chadi Nabhan, MD, Thomas J. Kipps, MD, PhD, Christopher Flowers, MD, Neil E. Kay, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Mark Kozloff, MD, Mark Weiss, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 5270.

https://doi.org/10.1182/blood.V126.23.5270.5270

Published: 2015

Journal Articles

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Anthony Mato, MD, Chadi Nabhan, MD, Christopher Flowers, MD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, David L. Grinblatt, MD, Nicole Lamanna, MD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 4483.

https://doi.org/10.1182/blood.V126.23.4483.4483

Published: 2015

Journal Articles

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Christopher Flowers, MD, Chadi Nabhan, MD, Neil E. Kay, MD, Anthony Mato, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Thomas J. Kipps, MD, PhD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 3284.

https://doi.org/10.1182/blood.V126.23.3284.3284

Published: 2015

NARROW

Connect ® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study

Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Disease Registry

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect ® MDS/AML Disease Registry

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only